AZD 7594

Drug Profile

AZD 7594

Alternative Names: AZ13189620; AZD-7594

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator AstraZeneca
  • Class Antiasthmatics; Small molecules
  • Mechanism of Action Glucocorticoid receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Asthma
  • Phase I Chronic obstructive pulmonary disease

Most Recent Events

  • 01 Nov 2016 AstraZeneca initiates a phase I trial for Chronic Obstructive Pulmonary Disease and Asthma (In voulnteers) in Germany (NCT02967159)
  • 01 Nov 2016 AstraZeneca initiates enrolment in a phase I pharmacokinetics trial in Healthy volunteers in Germany (NCT02928354)
  • 12 Oct 2016 AstraZeneca plans a phase I pharmacokinetics trial in Healthy volunteers in Germany (Inhalation, Powder) (NCT02928354)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top